References
Wada Y, Kushima R, Kodama M, Fukuda M, Fukuda K, Okamoto K, Ogawa R, Mizukami K, Okimoto T, Murakami K (2020) Histological changes associated with pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication. Virchows Arch. https://doi.org/10.1007/s00428-020-02805-9
Hattori T, Helpap B, Gedigk P (1982) The morphology and cell kinetics of pseudopyloric glands. Virchows Arch B Cell Pathol Incl Mol Pathol 39:31–40. https://doi.org/10.1007/BF02892834
Moszkowicz L (1922) Zur Histologie des Ulcus-breiten Magens. Arch Klin Chir 122:144–199
Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK, Wang TC (2002) TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109:193–204. https://doi.org/10.1172/JCI12529
Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA (1993) Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 105:1110–1116. https://doi.org/10.1016/0016-5085(93)90956-D
Goldenring JR (2018) Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa. J Pathol 245:132–137. https://doi.org/10.1002/path.5066
Hwang Y-J, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH (2018) Reversibility of atrophic gastritis and intestinal metaplasia after helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 47:380–390. https://doi.org/10.1111/apt.14424
Hunt RH, Camilleri M, Crowe SE, el-Omar EM, Fox JG, Kuipers EJ, Malfertheiner P, McColl KEL, Pritchard DM, Rugge M, Sonnenberg A, Sugano K, Tack J (2015) The stomach in health and disease. Gut 64:1650–1668. https://doi.org/10.1136/gutjnl-2014-307595
Graham DY, Rugge M, Genta RM (2019) Diagnosis: gastric intestinal metaplasia - what to do next? Curr Opin Gastroenterol 35:535–543. https://doi.org/10.1097/MOG.0000000000000576
Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F, Malfertheiner P (2018) OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol 113:1621–1628. https://doi.org/10.1038/s41395-018-0353-8
Acknowledgments
I would like to thank prof. Robert M. Genta from Baylor College of Medicine-Houston TX, USA, and Prof. Takanori Hattori from Shiga University of Medical Science-Japan. I am grateful to both of them for sharing with me their valuable experience on this attractive topic.
Funding
This work has been partly supported by a grant from the Italian Health Ministry’s Research program (ID: NET-2016-02363853).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rugge, M. Biologic profiles meet clinical priorities: incorporating pseudopyloric, and spasmolytic-expressing metaplasia in the assessment of gastric atrophy. Virchows Arch 477, 487–488 (2020). https://doi.org/10.1007/s00428-020-02814-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-020-02814-8